The pediatric clinics of the Michigan State University College of Human Medicine (MSU-CHM) consist of academic pediatricians serving two clinics with a patient population of 5200. The internal quality measures published by the MSU health team had consistently indicated our generic medications prescription rate to be very low, with an average of about 21% for the years 2009, 2010, and 2011. There was an earnest need to increase our generic medication prescription rates, which is considered an indicator of good practice. The stakeholders identified were physicians, nurses, care managers, and the health information technology (HIT) team.
Problem
Internal review of the Michigan State University (MSU) health team revealed that the College of Human Medicine (CHM) pediatric clinics lagged behind severely in prescribing generic medications, compared to their peers of other primary care large group practices, including family medicine, family practice, internal medicine, and specialty practices such as women's health. The overall average generic medication prescribing rate was 34% to 35% for the health team, whereas the rate was 21% for the CHM pediatric clinics.
Providers were prescribing high cost brand name medications in spite of the availability of low cost, viable approved generic medications. Apart from the impact on the patient family for the copay of these medications, there were multiple denials from insurance companies to cover the high cost brand names. Hence the staff had to convert these to low cost brand names or get prior authorization from the insurance companies, which was creating a huge impact on workflow and the efficient use of staff time. Most providers tend to remember brand names better than generic names due to advertisements, flyers, and also because of the easy searchable feature in the electronic medical record (EMR). Hence, providers and staff at CHM pediatric clinics wanted to work together to improve the service and save valuable dollars spent on brand name medications.
Background
The cost of prescription drugs as a part of total health care spending has been growing significantly across the world. [ year. Generic medications cost significantly less in copay (50% less) than brand name medications, and the savings may be more if medications are bought in retail. [3] This is especially true in the global market, as one study from India estimates the cost savings Page 1 of 3 for the average consumer could be up to 90% compared to brand name medications. [4] Another study estimates by switching just four medications to their generic equivalents China could save $370m, and the average cost savings by switching to generics would be 10% to 89% on the most common medications prescribed. [5] In the United States the cost for prescriptions is on the rise, and has risen significantly in the past decade. [6] In the United Kingdom it is a standard practice to prescribe generics, as 83% of the medications are dispensed in generic form. [7] There have been many health care policies carried out in countries such as Finland and Sweden, where generic substitutions are mandatory by the pharmacy and can be denied only by physician or patient preference. The cost saving in these countries is very significant, and estimated to be about 60% to 65% over brand name medications. [10, 11] In addition, Australia has introduced several health policies including incentives and a price reduction system for medications to be placed on the formulary, which is estimated to save their health care about $6.9 billion over the next 10 years. [10] 
Baseline measurement
To obtain a specific baseline measurement, we obtained data on the top 10 brand name medications prescribed across all providers in both clinics. The top six most prescribed brand name medications were controlled substances used for attention deficit hyperactivity disorder (ADHD). Medications which do not have generics, for example asthma medications such as Proair and Flovent, were not included in the baseline measurement. We also obtained the overall rate of generic prescription across all visits, which was 28% (n=615) for the last quarter of 2012. The rates from prior years obtained from the health team data showed generic prescribing rates to be an average of 20% for 2010 and 21.5% for 2011. Our providers were already doing a competent job in prescribing antibiotics in their generic form compared to the controlled substance medications and psychotropics.
See supplementary file: ds6546.docx -" Table 1 : brand name prescriptions before and after intervention; 
Design
The first step of the project was to identify the responsible stakeholders. Physician providers, nurses who refilled medications, care managers, and representatives from the health information technology (HIT) team were all identified as stakeholders. The team met every two to three months and started to work on strategies to improve the generic prescription rate. It was decided to collect baseline data about the top 10 brand name medications that were prescribed by the providers. Based on that data a plan was formulated to target medications for ADHD, asthma, and allergies.
HIT was requested to add the generic names for all the stimulants in a way that was easily searchable and recognizable. The names had a tag after them that indicated they were generic to a specific brand name. A clinic flow protocol was developed where the providers consciously started prescribing generic medications for the brand names when available, and since the nursing staff handled most of the refills for patients with ADHD and other conditions they were requested to change all brand names into generic medications. Patients' families were also informed of the change and assured that these changes would be monitored, and that all the generic medications were approved, low cost, and had comparable therapeutic efficacy. Quarterly reports were obtained from the MSU HIT team to monitor the progress.
Strategy
PDSA cycle 1: The stakeholders met every other week for one to two hours and started to work on methods to increase the generic prescription rates based on PDSA cycle. It was decided that nursing staff and physicians would prescribe new medications as generic equivalents, and nursing staff would try to switch the brand name medications to generic equivalents when they refilled medications for the patients. 
Results
After implementing the project over eight quarters, the overall rate of prescribing generic medications for all clinical visits improved from an average of 21% from the prior years to 53% at the end of There was some resentment from providers and nursing staff as they had to remember the generic names instead of brand names, which was a difficult task for most. As the clinic flow protocol was developed which stated the appropriate generic medication to be substituted for a particular brand name, there seemed to be more commitment from all. This project would not have been possible if not for the continued dedication among all stakeholders, especially the HIT. Reliable communication and follow up was imperative for such a project to succeed. There were concerns among patients when they suddenly saw their brand names were switched to generic equivalents, and the providers and nursing staff had to reassure the patients. We also ran into a unique problem of one insurance payer covering the brand name of amphetaminedextroamphetamine and not the generic equivalent. Since there are always questions about the comparison of therapeutic efficacy between brand and generic equivalents, active measures were put forward to follow up with patients if there were any concerns.
Conclusion
This project had a positive impact on the prescription rate of viable low cost approved generic equivalents instead of brand name medications. The plan will be to continue to improve the generic prescribing across all the clinics in the MSU health team based on this model. The rate of generic prescription improved significantly across all the providers in both clinics. This is also a good example of how information technology (the EMR) could be used to the advantage of the health care system and drive the cost of health care delivery. The cost impact of such projects is significant in health care and is a suitable example of system based practice.
Ultimately, generic medication utilization and cost savings will be dependent on various factors including availability of therapeutically equivalent generic medications, communication and commitment from pharmacies and physicians, physician commitment to keep health care costs low, patient education on the utilization of generic medications and the individual and global cost savings to health care, rigorous monitoring of the quality of generic medications, and financial incentives to the health care providers and pharmacies to switch to generics. [11, 12] 
